Kiora Pharmaceuticals, Inc. (KPRX)
NASDAQ: KPRX · Real-Time Price · USD
2.520
+0.030 (1.20%)
At close: Apr 17, 2026, 4:00 PM EDT
2.530
+0.010 (0.40%)
After-hours: Apr 17, 2026, 7:34 PM EDT
Kiora Pharmaceuticals Employees
Kiora Pharmaceuticals had 12 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
12
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$902,930
Market Cap
11.06M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 12 | 0 | - |
| Dec 31, 2023 | 12 | 0 | - |
| Dec 31, 2022 | 12 | -2 | -14.29% |
| Dec 31, 2021 | 14 | 0 | - |
| Dec 31, 2020 | 14 | 4 | 40.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 43 |
| BioLineRx | 24 |
| Theriva Biologics | 16 |
| NewcelX | 15 |
| Reviva Pharmaceuticals Holdings | 14 |
| Genprex | 13 |
| BioVie | 13 |
| Aprea Therapeutics | 8 |
KPRX News
- 5 days ago - Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway - Newsfile Corp
- 17 days ago - Kiora Pharmaceuticals Announces Management Team Changes - Newsfile Corp
- 25 days ago - Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials - Newsfile Corp
- 2 months ago - Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference - Newsfile Corp
- 2 months ago - Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board - Newsfile Corp
- 4 months ago - Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds - Newsfile Corp
- 5 months ago - Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases - Newsfile Corp
- 6 months ago - Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders - PRNewsWire